PCM1：与肺腺癌免疫浸润相关的潜在预后生物标志物,Current Proteomics

当前位置： X-MOL 学术 › Curr. Proteom. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

PCM1：与肺腺癌免疫浸润相关的潜在预后生物标志物
Current Proteomics ( IF 0.5 ) Pub Date : 2023-12-08 , DOI: 10.2174/0115701646270898231123065507
Zhihua Guo ₁ , Jinghao Liang ₁ , Xin Zhang ₁ , Qing Ai ₁ , Zixian Xie ₁ , Haonan Zhao ₁ , Fayuan Wu ₁ , Zhaofeng Tan ₁ , Weiqiang Yin ₁ , Linghua Ji ₁

Affiliation

背景：最近的研究证实了中心粒周材料 1 (PCM1) 在几种恶性肿瘤细胞系中的作用，但其在肺腺癌 (LUAD) 中的具体生物学功能仍不清楚。目的：为了解决这一差距，本研究分析了 411 个 LUAD 和对照样本，以使用 Cox 回归分析评估 PCM1 的预后价值。方法：还分析了与 PCM1 共表达的多个基因，以研究 PCM1 所涉及的生物学过程和作用。构建以PCM1为关键基因的内源竞争网络，揭示其在LUAD中的调控和竞争关系。该研究基于免疫浸润分析，进一步探讨了PCM1在不同表达组中的免疫学特征。结果：这些发现表明，较高的 PCM1 表达水平与更好的生存预后相关，可能是由于其对 RHOC 的拮抗作用。免疫学浸润分析显示，PCM1 与各种免疫细胞浸润水平（包括 CD4+ T 细胞、幼稚 B 细胞、M2 巨噬细胞和肥大细胞）之间存在显着相关性。然而，PCM1 与 MSI、TMB 或干性之间没有显着关系，尽管它与 m6A 基因呈正相关。 PCM1 表达较低的患者对 CTLA-4 治疗反应更好。该研究还估计，一些化疗和靶向药物可能对治疗 PCM1 水平高的患者有效。 PCM1主要表达于细胞质和膜结构。结论：PCM1 由于与免疫细胞浸润密切相关且能够增强抗癌治疗敏感性，因此显示出作为 LUAD 预后生物标志物的潜力。

"点击查看英文标题和摘要"

PCM1: A Potential Prognostic Biomarker Correlated with Immune Infiltration in Lung Adenocarcinoma

Background: Recent studies have validated the role of Pericentriolar Material 1 (PCM1) in several malignant tumour cell lines, but its specific biological function in lung adenocarcinoma (LUAD) remains unclear. Objective: To address this gap, this study analyzed 411 LUAD and control samples to evaluate the prognostic value of PCM1 using Cox regression analysis. Methods: Multiple genes co-expressed with PCM1 were also analyzed to investigate the biological processes and roles involved in PCM1. An endogenous competitive network with PCM1 as the key gene was constructed to uncover its regulatory and competitive relationships in LUAD. The study further explored the immunological characteristics of PCM1 in different expression groups based on immune infiltration analysis. Results: These findings indicated that higher PCM1 expression levels were associated with better survival prognoses, possibly due to its antagonistic effects on RHOC. Immunological infiltration analysis revealed a significant correlation between PCM1 and various immune cell infiltration levels, including CD4+ T cells, naïve B cells, M2 macrophages, and mast cells. However, there was no significant relationship between PCM1 and MSI, TMB, or stemness, although it was positively correlated with m6A genes. Patients with lower PCM1 expression responded better to CTLA-4 therapy. The study also estimated that some chemotherapeutic and targeted agents might be effective in treating patients with high PCM1 levels. PCM1 was mainly expressed in the cytoplasmic and membranous structures. Conclusion: PCM1 shows potential as a prognostic biomarker for LUAD due to its strong correlation with immune cell infiltration and its ability to enhance anticancer treatment sensitivity.

更新日期：2023-12-08

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南